TY - JOUR
T1 - Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
AU - Goyal, Jatinder
AU - Antonarakis, Emmanuel S.
PY - 2012/10/28
Y1 - 2012/10/28
N2 - Patients with castration-resistant prostate cancer (CRPC) frequently have metastases to the bone, which may cause pain and lead to a deterioration in quality-of-life. Bone-seeking radiopharmaceuticals are agents which, when administered systemically, localize to the site of bone metastases and deliver focal radiation there. In this review, we will summarize the current literature on bone-targeting radiopharmaceuticals for CRPC, focusing on strontium-89, samarium-153, rhenium-186 and radium-223. We will discuss their indications, clinical efficacy, and toxicities and highlight some of the challenges in optimizing treatment with these agents. Historically, clinical trials with these drugs have failed to demonstrate survival improvements, restricting their use for palliative purposes only. Radium-223 is the first agent in this class to show an overall survival advantage in CRPC patients with bone metastases. This landmark finding will likely have a considerable impact on the treatment paradigm of bone-metastatic CRPC, and will pave the way for further developments in the future.
AB - Patients with castration-resistant prostate cancer (CRPC) frequently have metastases to the bone, which may cause pain and lead to a deterioration in quality-of-life. Bone-seeking radiopharmaceuticals are agents which, when administered systemically, localize to the site of bone metastases and deliver focal radiation there. In this review, we will summarize the current literature on bone-targeting radiopharmaceuticals for CRPC, focusing on strontium-89, samarium-153, rhenium-186 and radium-223. We will discuss their indications, clinical efficacy, and toxicities and highlight some of the challenges in optimizing treatment with these agents. Historically, clinical trials with these drugs have failed to demonstrate survival improvements, restricting their use for palliative purposes only. Radium-223 is the first agent in this class to show an overall survival advantage in CRPC patients with bone metastases. This landmark finding will likely have a considerable impact on the treatment paradigm of bone-metastatic CRPC, and will pave the way for further developments in the future.
KW - Bone metastases
KW - Castration-resistant prostate cancer
KW - Radiopharmaceuticals
KW - Radium-223
KW - Samarium-153
KW - Strontium-89
UR - http://www.scopus.com/inward/record.url?scp=84863093187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863093187&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2012.04.001
DO - 10.1016/j.canlet.2012.04.001
M3 - Review article
C2 - 22521546
AN - SCOPUS:84863093187
SN - 0304-3835
VL - 323
SP - 135
EP - 146
JO - Cancer Letters
JF - Cancer Letters
IS - 2
ER -
